Clinical Trials Browser

Phase 1/2 × Recruiting × Diffuse Intrinsic Pontine Glioma × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

NCT06465199 2026-04-13

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Phase 1/2 Recruiting

289 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07501156 2026-03-30

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Phase 1/2 Recruiting

30 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT04870944 2026-02-24

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT05956821 2025-12-08

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase 1/2 Recruiting

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

Clinical Trials

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age